A Phase 2A, Randomized, Blinded, Placebo and Active Controlled, 2 Period Crossover Study to Assess the Analgesic Efficacy, Safety, and Tolerability of ADL5747 in Subjects With Postherpetic Neuralgia.
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2015
At a glance
- Drugs ADL 5747 (Primary) ; Pregabalin
- Indications Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Adolor Corporation
- 07 Jul 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
- 07 Jun 2011 Planned end date changed from 1 Jan 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
- 07 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.